Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05608408 · ClinicalTrials.gov registry record · NA
PRIME: PReservIng Memory in Epilepsy
A NA study of Mesial Temporal Lobe Epilepsy, sponsored by Nitin Tandon.
- Recruiting
- Registry status
- NA
- Development phase
- 8
- Enrollment target
- 2
- Study locations
NCT05608408: Recruiting NA study of Mesial Temporal Lobe Epilepsy, sponsored by Nitin Tandon.
NCT05608408 is a NA study of Mesial Temporal Lobe Epilepsy that is actively recruiting participants, run by Nitin Tandon. The registered enrollment target is 8 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05608408, a NA study of Mesial Temporal Lobe Epilepsy, is actively recruiting participants, sponsored by Nitin Tandon.
- RECRUITING
- Registry status
- NA
- Development phase
- 8 participants
- Enrollment target
- 2
- Study locations
Study Summary
In this study, participants will receive unilateral Deep Brain Stimulation (DBS) for treatment of epilepsy, with network-based stimulation targets specifically defined using a stereo-electro-encephalographic evaluation and chronic recordings using the Medtronic Percept™ primary cell (PC) Neurostimulator DBS System with BrainSense™ Technology. The hypothesis is that, compared to no stimulation or to standard duty cycle high frequency stimulation, epilepsy neuromodulation using low frequency stimulation and informed by network architecture in patients with epilepsy that arises in a hippocampus that also subserves memory - epilepsy in a precious hippocampus (EPH) - will result in a significant decrease in seizure frequency and severity, paralleled by a decrease in EEG spike counts and improved memory function.
Conditions Studied
Interventions
- DEVICE Low Frequency Stimulation (LFS) of site with the Medtronic Percept PC system
- DEVICE Standard of Care (SOC) High Frequency Stimulation of the Anterior Nucleus of the Thalamus (ANT) with the Medtronic Percept PC system
Study Locations (2)
Minnesota
- Mayo Clinic - Rochester
Texas
- The University of Texas Science Center at Houston - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2023-11-16 |
| Est. Completion | 2028-03-31 |
| Phase | NA |
What NCT05608408 shows while recruiting
NCT05608408 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Mesial Temporal Lobe Epilepsy appearing as the primary indexed condition, and to 2 interventions - of which Low Frequency Stimulation (LFS) of site with the Medtronic Percept PC system is the first listed.
NCT05608408 reports a single indexed study location in Minnesota, Texas.
Frequently Asked Questions
What is clinical trial NCT05608408 about?
NCT05608408 is a clinical study titled "PRIME: PReservIng Memory in Epilepsy". In this study, participants will receive unilateral Deep Brain Stimulation (DBS) for treatment of epilepsy, with network-based stimulation targets specifically defined using a stereo-electro-encephalographic evaluation and chronic recordings using the Medtronic Percept™ primary cell (PC) Neurostimul...
What is the current status of trial NCT05608408?
This trial is currently recruiting. It is a NA study. The enrollment target is 8 participants. The study started on 2023-11-16. Estimated completion is 2028-03-31.
What conditions does trial NCT05608408 study?
This clinical trial studies the following conditions: Mesial Temporal Lobe Epilepsy.
What interventions are being tested in trial NCT05608408?
The interventions under investigation include: Low Frequency Stimulation (LFS) of site with the Medtronic Percept PC system (DEVICE), Standard of Care (SOC) High Frequency Stimulation of the Anterior Nucleus of the Thalamus (ANT) with the Medtronic Percept PC system (DEVICE).
Who is sponsoring clinical trial NCT05608408?
This trial is sponsored by Nitin Tandon, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05608408 being conducted?
This trial has 2 study locations across Minnesota, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mesial Temporal Lobe Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05608408's enrollment target sits among peer trials
8 1977th of 2000 higher than 19 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI